PEG-MGF: Sourcing, Documentation and Price
PEG-MGF is a pegylated synthetic analogue of mechano growth factor (MGF), the IGF-1Ec splice variant of the IGF-1 gene. This page covers what the research literature records about it, what documentation a laboratory shou
PEG-MGF is the pegylated form of mechano growth factor (MGF), also written as PEGylated MGF and, in the older literature, as PEG-IGF-1Ec. MGF is a splice variant of the insulin-like growth factor 1 (IGF1) gene, generated by alternative splicing that inserts an extra exon (exon 5 in the rodent gene, exon 5/6 in the human gene) and produces the IGF-1Ec transcript. The peptide sequence of the human Ec variant is a 24-amino-acid carboxy-terminal extension (the “MGF E-domain”) fused to the mature IGF-1 sequence; the isolated E-domain peptide is commonly referred to as MGF. PEGylation attaches one or more polyethylene glycol chains to the peptide backbone, a modification used across peptide chemistry to alter plasma residence time and reduce proteolytic clearance. The evidence block supplied for this page does not give a molecular formula, a CAS number or a stated molecular weight for PEG-MGF, and none is asserted here.
The work in this area centres on the IGF-1 receptor (IGF-1R) and on the GH–IGF-1 axis more broadly, the endocrine pathway that links growth hormone secretion to hepatic and local IGF-1 production [1].
Research Studies
PEG-MGF and the GH–IGF-1 axis as a category of research compound
A review of performance-enhancing peptides that modulate the GH–IGF-1 axis describes the agents most commonly encountered in clinical practice and in online self-administration protocols [1]. The categories named in that review are GHRH analogues (sermorelin, tesamorelin, CJC-1295 with and without drug affinity complex), growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD9604 (hGH 176-191), and IGF-1 analogues [1]. The review frames these materials as unregulated peptides marketed as “research compounds” [1]. PEG-MGF sits within the IGF-1 analogue branch of that taxonomy rather than the secretagogue branch, because its parent sequence derives from the IGF1 gene product and not from a ghrelin-receptor or GHRH-receptor ligand.
PEG-MGF and the IGF-1Ec splice variant
The distinguishing feature of MGF relative to mature IGF-1 is the E-domain extension created by alternative splicing of the IGF1 gene. The review cited above groups IGF-1 analogues together as a class of GH–IGF-1 axis modulators encountered in self-administration settings [1]. It does not report a controlled trial of PEG-MGF in any population, and no such trial appears in the evidence supplied here. Any statement that PEG-MGF produces a specific physiological effect in humans would therefore be unsupported by the material available for this page.
PEG-MGF and pegylated growth hormone comparators
Pegylation as a strategy is documented in the clinical literature for a related but distinct molecule: pegylated recombinant human growth hormone (PEG-rhGH). A registered study of PEG-somatropin injection in children with Turner syndrome was designed to explore the optimal dose of PEG-rhGH, to preliminarily evaluate its safety and efficacy, and to provide evidence for dosing in a Phase 3 trial [8]. That study concerns pegylated growth hormone, not PEG-MGF, and the population is paediatric Turner syndrome patients [8]. It is cited here only because it is the one pegylated GH-axis agent with a registered clinical protocol in the evidence block; it should not be read as evidence about PEG-MGF itself.
PEG-MGF and the absence of registered clinical protocols
No registered study of PEG-MGF appears in the evidence supplied. The registered protocols available concern unrelated molecules and indications: trontinemab in early symptomatic Alzheimer's disease [2], a pre-screening study for Roche Alzheimer's interventional studies [3], semaglutide in early Alzheimer's disease (EVOKE [4] and EVOKE Plus [5]), lipoprotein(a) epidemiology in established cardiovascular disease [6], and ticagrelor plus ASA versus placebo plus ASA after acute stroke or transient ischaemic attack [7]. None of these involves MGF, PEG-MGF, or any IGF-1 splice variant. The practical consequence for a laboratory is that there is no clinical protocol to reference when designing a study around this material, and no published human safety or pharmacokinetic dataset to cite.
PEG-MGF and the documentation a supplier should provide
Because the compound sits in the unregulated “research compound” category described in the review [1], the documentation accompanying a vial carries most of the analytical weight. A laboratory sourcing PEG-MGF should expect, at minimum, the following items, and should treat their absence as a reason to look elsewhere.
| Document | What it establishes | What it does not establish |
|---|---|---|
| Certificate of analysis (CoA) | Identity and purity for the specific lot | Sterility, endotoxin, or biological activity |
| HPLC trace | Purity as a percentage, retention profile | Correct sequence |
| Mass spectrometry | Molecular mass consistent with the expected peptide and PEG adduct | Position or number of PEG chains, unless stated |
| Peptide sequence | Confirms the IGF-1Ec E-domain construct | Folding or aggregation state |
| Lot number and retest date | Traceability and stability window | Shipping temperature history |
PEGylation introduces a specific documentation problem: a mass spectrum of a pegylated peptide shows a distribution rather than a single peak, because the PEG chains themselves are polydisperse. A CoA that reports a single sharp mass for a pegylated product without explaining the PEG distribution is not describing the material accurately. The supplier should state the PEG molecular weight range and the average degree of substitution.
PEG-MGF and price determinants
Price for research-grade PEG-MGF is driven by factors that are largely independent of the peptide sequence itself. The table below sets out the usual drivers.
| Factor | Effect on price |
|---|---|
| Scale of synthesis | Larger batch size lowers per-milligram cost |
| Purity grade | Higher HPLC purity requires additional purification steps |
| PEGylation step | Adds a conjugation and a second purification stage |
| Analytical package | Full CoA with MS and HPLC adds cost but is the basis for reproducibility |
| Vial format and fill | Smaller fills carry proportionally higher handling cost |
| Cold-chain shipping | Lyophilised material is cheaper to ship than reconstituted |
None of these factors speaks to whether the material will behave as a researcher hopes in an assay. Price reflects manufacturing and analytical effort, not biological potency, and the review's characterisation of this category as unregulated [1] means that no external body verifies the label claim on a vial.
PEG-MGF and handling in the laboratory
Standard practice for research peptides applies. Lyophilised PEG-MGF should be stored desiccated at low temperature and protected from light; repeated freeze–thaw cycles of reconstituted material degrade peptide integrity. Reconstitution solvent choice affects aggregation behaviour, and the PEG chain changes the solubility profile relative to the unpegylated E-domain peptide. Because the evidence block contains no stability study of PEG-MGF, no specific storage duration or solvent recommendation is asserted here.
PEG-MGF and the limits of the current evidence
The single review in the evidence block that addresses this compound class does so at the level of taxonomy and clinical encounter, not at the level of controlled experimental results for PEG-MGF [1]. It records that these peptides are encountered in self-administration protocols and that they are unregulated [1]. It does not report animal data, in vitro data, or human data specific to PEG-MGF. A researcher planning work with this material should therefore treat the published base as thin and should design studies that stand on their own internal controls rather than on prior reported effects.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and nothing on this page is medical information. We do not provide dosing, administration or medical guidance for any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
- [2] A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease. https://clinicaltrials.gov/study/NCT07170150
- [3] Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies. https://clinicaltrials.gov/study/NCT07177352
- [4] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE). https://clinicaltrials.gov/study/NCT04777396
- [5] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus). https://clinicaltrials.gov/study/NCT04777409
- [6] Lipoprotein(a) in Patients With Cardiovascular Disease (CVD). https://clinicaltrials.gov/study/NCT03887520
- [7] THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death. https://clinicaltrials.gov/study/NCT03354429
- [8] A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome. https://clinicaltrials.gov/study/NCT03189160